The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
| Title |
Anticholinergic medication for non‐clozapine neuroleptic‐induced hypersalivation in people with schizophrenia
|
|---|---|
| Published in |
Cochrane database of systematic reviews, December 2013
|
| DOI | 10.1002/14651858.cd009546.pub2 |
| Pubmed ID | |
| Authors |
Adib Essali, Anas Rihawi, Mohammad Altujjar, Bishr Alhafez, Amjad Tarboush, Nahla Alhaj Hasan |
| Abstract |
Treatment of schizophrenia depends heavily on neuroleptic drugs. Hypersalivation is a common side effect when people with schizophrenia are treated with neuroleptic drugs. Hypersalivation can be an embarrassing and stigmatising problem, can affect quality of life and can result in discontinuation of neuroleptic treatment. It can also be difficult to treat. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 30% |
| India | 1 | 10% |
| New Zealand | 1 | 10% |
| Unknown | 5 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 70% |
| Practitioners (doctors, other healthcare professionals) | 2 | 20% |
| Scientists | 1 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 138 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Chile | 1 | <1% |
| Germany | 1 | <1% |
| Unknown | 136 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 19 | 14% |
| Student > Bachelor | 17 | 12% |
| Student > Master | 14 | 10% |
| Student > Ph. D. Student | 13 | 9% |
| Student > Doctoral Student | 7 | 5% |
| Other | 25 | 18% |
| Unknown | 43 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 35 | 25% |
| Psychology | 17 | 12% |
| Nursing and Health Professions | 7 | 5% |
| Social Sciences | 6 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
| Other | 15 | 11% |
| Unknown | 54 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 April 2024.
All research outputs
#4,894,471
of 26,215,093 outputs
Outputs from Cochrane database of systematic reviews
#7,090
of 13,194 outputs
Outputs of similar age
#52,223
of 323,706 outputs
Outputs of similar age from Cochrane database of systematic reviews
#136
of 232 outputs
Altmetric has tracked 26,215,093 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,194 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.5. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,706 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 232 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.